Infliximab treatment of pediatric refractory Crohn's disease: A case report

Turkish Journal of Gastroenterology

Volumn 17, Issue 2, 2006, Pages 133-136

  Aşik Akman, Sezin ^a,c   Arikan, Çiǧdem ^b   Sözen, Gülben ^a   Öztürk, Can ^a   Yaǧci, Raşit Vural ^b  

^a SSK Tepecik Teaching Hospital   (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^c NONE   (Turkey)

Author keywords

Childhood; Crohn's disease; Infliximab

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; INFLIXIMAB; PREDNISOLONE; STEROID;

ADOLESCENT; ARTHRALGIA; ARTICLE; BARIUM ENEMA; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DRUG DOSE REDUCTION; ENTEROENDOCRINE CELL; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; MALE; MOUTH LESION; PEDIATRIC WARD; PHYSICAL EXAMINATION; PNEUMONIA; SMALL INTESTINE DISEASE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; REMISSION INDUCTION;

EID: 34147140420     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Valentini G, Guidi L, Costanzo M, et al. An update on the medical treatment of Crohn's disease. Panminerva Med 2003; 45: 15-22.
2. Levine A, Milo T, Buller H, Markowitz J. Consensus and controversy in the management of pediatric Crohn's disease: an international survey. J Pediatr Gastroenterol Nutr 2003; 36: 464-9.
3. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
4. Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev 2002; 15: 79-94.
5. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (Remicade) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003; 98: 717-20.
6. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003; 18: 425-31.
7. Buller H, Chin S, Kirschner B, et al. Working group on inflammatory bowel disease in children and adolescents. Report of the Working Groups of the World Congress of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2002; 35 (Suppl 2): S151-8.
8. Zimmermann-Nielsen E, Agnholt J, Thorlacius-Ussing O, et al. Complement activation in plasma before and after infliximab treatment in Crohn disease. Scand J Gastroenterol 2003; 38: 1050-4.
9. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 Feb26; 350: 934-6.
10. Fuss IJ. Treatment of ulcerative colitis with Infliximab: Are we there yet? J Pediatr Gastroenterol Nutr 2004; 38: 247-9.
11. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease Ca2 Study Group. N Engl J Med 1997; 337: 1029-35.
12. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.